MedTrace Logo

Feasibility And Safety of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation

NCT02404467 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 502

Last updated 2020-10-23

No results posted yet for this study

Summary

The hypothesis behind this study is that there is a proportion of patients considered high or intermediate risk for surgery, but relatively low risk for TAVI, which can be discharged early after the procedure (within the first 2-3 days) without additional risks. Therefore, when performed in safety, an early discharge may cut periprocedural TAVI costs significantly.

Conditions

  • Aortic Stenosis

Interventions

DEVICE

TF TAVI

Follow-up Observation of patients having received a TF-TAVI

Sponsors & Collaborators

  • Edwards Lifesciences

    collaborator INDUSTRY

  • Institut für Pharmakologie und Präventive Medizin

    lead NETWORK

Principal Investigators

  • Corrado Tamburino, MD · Ferrarotto Hospital, University of Catania

  • Marco Barbanti, MD · Ferrarotto Hospital, University of Catania

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-11-30
Completion
2019-07-31

Countries

  • Italy
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02404467 on ClinicalTrials.gov